{"id":"https://openalex.org/W2000969578","doi":"https://doi.org/10.1097/01.inf.0000133045.45316.6a","title":"Long Term Tolerability and Safety of Enfuvirtide for Human Immunodeficiency Virus 1-Infected Children","display_name":"Long Term Tolerability and Safety of Enfuvirtide for Human Immunodeficiency Virus 1-Infected Children","publication_year":2004,"publication_date":"2004-08-01","ids":{"openalex":"https://openalex.org/W2000969578","doi":"https://doi.org/10.1097/01.inf.0000133045.45316.6a","mag":"2000969578","pmid":"https://pubmed.ncbi.nlm.nih.gov/15295220"},"language":"en","primary_location":{"id":"doi:10.1097/01.inf.0000133045.45316.6a","doi":"https://doi.org/10.1097/01.inf.0000133045.45316.6a","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.inf.0000133045.45316.6a","pdf_url":null,"source":{"id":"https://openalex.org/S109369870","display_name":"The Pediatric Infectious Disease Journal","issn_l":"0891-3668","issn":["0891-3668","1532-0987"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Pediatric Infectious Disease Journal","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103829550","display_name":"Joseph A. Church","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1336910626","display_name":"Children's Hospital Los Angeles","ror":"https://ror.org/00412ts95","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1336910626"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Joseph A. Church","raw_affiliation_strings":["Childrens Hospital Los Angeles, Division of Clinical Immunology and Allergy, CA 90027, USA. jchurch@chla.usc.edu","Address for reprints: Joseph A. Church, MD, Childrens Hospital Los Angeles, Division of Clinical Immunology and Allergy, 4650 Sunset Boulevard, Mail Stop 75, Los Angeles, CA 90027. Fax 323-666-4627","E-mail [email\u00a0protected]"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Childrens Hospital Los Angeles, Division of Clinical Immunology and Allergy, CA 90027, USA. jchurch@chla.usc.edu","institution_ids":["https://openalex.org/I1336910626"]},{"raw_affiliation_string":"Address for reprints: Joseph A. Church, MD, Childrens Hospital Los Angeles, Division of Clinical Immunology and Allergy, 4650 Sunset Boulevard, Mail Stop 75, Los Angeles, CA 90027. Fax 323-666-4627","institution_ids":["https://openalex.org/I1336910626"]},{"raw_affiliation_string":"E-mail [email\u00a0protected]","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Michael Hughes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Hughes","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100332846","display_name":"Jie Chen","orcid":"https://orcid.org/0000-0001-7925-3729","observed_orcids":["https://orcid.org/0000-0001-7925-3729","https://orcid.org/0000-0001-6757-6416"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jie Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017796724","display_name":"Paul E Palumbo","orcid":"https://orcid.org/0000-0003-4434-8837","observed_orcids":["https://orcid.org/0000-0003-4434-8837"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul Palumbo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086432190","display_name":"LYNNE M. MOFENSON","orcid":"https://orcid.org/0000-0002-2818-9808","observed_orcids":["https://orcid.org/0000-0002-2818-9808"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lynne M. Mofenson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087025095","display_name":"Patricia DeLora","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patricia Delora","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041321008","display_name":"Elizabeth Smith","orcid":"https://orcid.org/0000-0002-6519-6636","observed_orcids":["https://orcid.org/0000-0002-6519-6636"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elizabeth Smith","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113532723","display_name":"ANDREW A. WIZNIA","orcid":"https://orcid.org/0000-0001-7487-1894","observed_orcids":["https://orcid.org/0000-0001-7487-1894"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew Wiznia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108519303","display_name":"Elizabeth Hawkins","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elizabeth Hawkins","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028155919","display_name":"Prakash Rao Sista","orcid":"https://orcid.org/0009-0006-1019-2394","observed_orcids":["https://orcid.org/0009-0006-1019-2394"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Prakash Sista","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5049003583","display_name":"Coleen K. Cunningham","orcid":"https://orcid.org/0000-0002-7725-3052","observed_orcids":["https://orcid.org/0000-0002-7725-3052"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Coleen K. Cunningham","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5103829550"],"corresponding_institution_ids":["https://openalex.org/I1336910626"],"apc_list":null,"apc_paid":null,"fwci":5.5048,"has_fulltext":false,"cited_by_count":42,"citation_normalized_percentile":{"value":0.95749524,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"23","issue":"8","first_page":"713","last_page":"718"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/enfuvirtide","display_name":"enfuvirtide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hiv-1","display_name":"HIV-1","score":0.8190000057220459},{"id":"https://openalex.org/keywords/pediatric-hiv","display_name":"pediatric HIV","score":0.8859999775886536},{"id":"https://openalex.org/keywords/hiv-entry-inhibitors","display_name":"HIV entry inhibitors","score":0.7039999961853027},{"id":"https://openalex.org/keywords/long-term-tolerability","display_name":"long-term tolerability","score":0.871999979019165},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.8610000014305115},{"id":"https://openalex.org/keywords/injection-site-reactions","display_name":"injection site reactions","score":0.8880000114440918},{"id":"https://openalex.org/keywords/virologic-failure","display_name":"virological failure","score":0.8880000114440918},{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.8669999837875366},{"id":"https://openalex.org/keywords/cd4-count","display_name":"CD4 count","score":0.8050000071525574},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.890999972820282},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6399999856948853},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.550000011920929},{"id":"https://openalex.org/keywords/edema","display_name":"edema","score":0.4009999930858612}],"concepts":[{"id":"https://openalex.org/C2778037500","wikidata":"https://www.wikidata.org/wiki/Q423327","display_name":"Enfuvirtide","level":5,"score":0.9853320121765137},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8959051966667175},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7288598418235779},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6174200177192688},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5434785485267639},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.5407426953315735},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5309588313102722},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.34443652629852295},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.28762850165367126},{"id":"https://openalex.org/C2776258796","wikidata":"https://www.wikidata.org/wiki/Q5590520","display_name":"Gp41","level":4,"score":0.05608609318733215},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.0},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000077560","descriptor_name":"Enfuvirtide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002675","descriptor_name":"Child, Preschool","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010446","descriptor_name":"Peptide Fragments","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012367","descriptor_name":"RNA, Viral","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000472","qualifier_name":"pathogenicity","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015700","descriptor_name":"HIV Envelope Protein gp41","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023581","descriptor_name":"HIV Fusion Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D023581","descriptor_name":"HIV Fusion Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D023581","descriptor_name":"HIV Fusion Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/01.inf.0000133045.45316.6a","doi":"https://doi.org/10.1097/01.inf.0000133045.45316.6a","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.inf.0000133045.45316.6a","pdf_url":null,"source":{"id":"https://openalex.org/S109369870","display_name":"The Pediatric Infectious Disease Journal","issn_l":"0891-3668","issn":["0891-3668","1532-0987"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Pediatric Infectious Disease Journal","raw_type":"journal-article"},{"id":"pmid:15295220","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15295220","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Pediatric infectious disease journal","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8799999952316284}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W2014820071","https://openalex.org/W2015796602","https://openalex.org/W2032020323","https://openalex.org/W2036656105","https://openalex.org/W2040506631","https://openalex.org/W2041505318","https://openalex.org/W2078978810","https://openalex.org/W2102155948","https://openalex.org/W2112129496","https://openalex.org/W2133649749"],"related_works":["https://openalex.org/W2064435536","https://openalex.org/W2064469588","https://openalex.org/W2002652763","https://openalex.org/W2181402719","https://openalex.org/W2142539348","https://openalex.org/W2318180004","https://openalex.org/W2040978448","https://openalex.org/W2129106897","https://openalex.org/W191242174","https://openalex.org/W4241572108"],"abstract_inverted_index":{"BACKGROUND:":[0],"Enfuvirtide,":[1],"a":[2,17,105,350,370],"peptide":[3],"inhibitor":[4],"of":[5,16,20,31,34,53,62,84,97,119,154,163,166,180,192,201,228,251,264,267,322,352,373],"human":[6],"immunodeficiency":[7],"virus":[8],"(HIV)-1-host":[9],"cell":[10,142],"membrane":[11],"fusion,":[12],"is":[13],"the":[14,23,47,80,229,260,268,293,317,345],"first":[15,81,261],"new":[18,303],"class":[19],"antiretroviral":[21,29],"agents,":[22],"entry":[24],"inhibitors.":[25],"The":[26],"safety":[27,52],"and":[28,51,108,131,139,171,216,238,247,295,355],"activity":[30],"enfuvirtide":[32,85,159,325,343],"treatment":[33,164,273,306],"24":[35,82,178,262,276],"weeks":[36,83,92,96,153,214,245,263,348],"in":[37,226,358,378],"HIV-1-infected":[38,379],"children":[39,219,253,301,323,380],"has":[40],"been":[41],"previously":[42],"documented.":[43],"Here":[44],"we":[45],"present":[46],"long":[48,383],"term":[49],"tolerability":[50],"enfuvirtide.":[54,308],"METHODS:":[55],"Fourteen":[56],"children,":[57],"4":[58,266],"to":[59,94,117,169,184,286,312,316],"12":[60,269],"years":[61],"age,":[63],"with":[64,114,307],"incompletely":[65],"suppressed":[66],"HIV-1":[67,136,203,327],"infection":[68],"were":[69,88,284],"evaluated.":[70],"Enfuvirtide":[71,363],"was":[72,310,364],"administered":[73],"twice":[74],"daily":[75],"by":[76],"subcutaneous":[77],"injection.":[78],"After":[79],"dosing,":[86],"subjects":[87,188,270],"evaluated":[89],"every":[90],"8":[91],"up":[93],"96":[95,152,347,385],"therapy.":[98],"At":[99],"each":[100,102,127],"visit,":[101],"subject":[103,233],"had":[104,254,326,349],"physical":[106],"examination":[107],"an":[109,167,197],"assessment":[110],"for":[111,297,344,369,381],"adverse":[112,223],"events":[113,224],"particular":[115],"attention":[116],"evaluation":[118],"injection":[120,256,374],"site":[121,257,375],"reactions.":[122,279],"Laboratory":[123],"studies":[124],"obtained":[125],"at":[126,150,244,337],"visit":[128],"included":[129],"hematology":[130],"blood":[132],"chemistry":[133],"values,":[134],"plasma":[135,202],"RNA":[137,204,328],"concentrations":[138],"CD4+":[140,359],"T":[141,360],"counts.":[143],"RESULTS:":[144],"Of":[145],"14":[146,252],"subjects,":[147],"6":[148],"completed":[149],"least":[151],"treatment.":[155],"One":[156],"child":[157,173],"discontinued":[158,175,189],"after":[160,176,292],"22":[161],"days":[162],"because":[165,179,191],"aversion":[168],"injections,":[170],"1":[172,232,239,331],"electively":[174],"week":[177,275,338],"surgical":[181],"complications":[182],"unrelated":[183],"study":[185,190,230,318],"drug.":[186,319],"Four":[187],"virologic":[193],"failure,":[194],"defined":[195],"as":[196,382,384],"increase":[198,357],"or":[199],"persistence":[200],"1.0":[205],"copies/mL":[206,333],"above":[207],"baseline,":[208],"which":[209],"occurred":[210],"between":[211],">or":[212],"=log10":[213],"40":[215],"63.":[217],"Two":[218],"experienced":[220],"grade":[221,235,241],"3":[222,236,242],"resulting":[225],"discontinuation":[227],"drug;":[231],"developed":[234,240,291,302],"thrombocytopenia":[237],"edema":[243],"65":[246,353],"77,":[248],"respectively.":[249],"Eleven":[250],"local":[255,278,282],"reactions":[258,283],"during":[259,305],"treatment,":[265],"who":[271],"continued":[272],"beyond":[274],"reported":[277],"Generally,":[280],"these":[281],"1-":[285],"3-cm":[287],"tender":[288],"nodules":[289],"that":[290],"injections":[294],"lasted":[296],"1-2":[298],"days.":[299],"Twelve":[300],"diagnoses":[304],"None":[309],"judged":[311],"be":[313],"definitively":[314],"related":[315],"Thirty-six":[320],"percent":[321],"starting":[324],"levels":[329,336],">":[330],"log10":[332],"below":[334],"baseline":[335],"96.":[339],"Children":[340],"remaining":[341],"on":[342],"entire":[346],"median":[351],"cells/mm":[354],"9%":[356],"cells.":[361],"CONCLUSIONS:":[362],"generally":[365],"safe":[366],"and,":[367],"except":[368],"high":[371],"rate":[372],"reactions,":[376],"well-tolerated":[377],"weeks.":[386]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}